by Daniel N. Galbraith, PhD
Volume 5, Issue 4 (Winter 2006)
The biologics market, although difficult to estimate, is currently thought to be in excess of $20 billion. In recent years, the growth in the novel therapeutics market has continued to exceed all but the most optimistic of expectations. The number of products in early stage trials may already be over 1,000, with an estimated 40 or so additional products in the process of finally being released to the market. The biologics market is led by relatively few “blockbuster” drugs, but the breadth of novel products continues to expand. This has resulted in exciting times for clinicians but has resulted in concern related to the bottleneck of production capacities for these drugs, as well as the pressure from healthcare agencies to reduce the cost of goods…
Citation:
Galbraith DN. The Potential for the Use of Baculovirus Expression Vector Systems to Produce Recombinant Protein for Clinical Use. BioProcess J, 2006; 5(4): 8-13. https://doi.org/10.12665/J54.Galbraith